Leela Barham

Views & Analysis

What can Linux and Mozilla teach ICER about how to do drug value assessments?

What’s affordable anyway? The future of NHS drug spending

The single biggest monetary difference that can be made to the successor to the UK’s 2019 Voluntary Scheme for branded medicines pricing and access (VPAS) is to address the question of how

Views & Analysis

Time for a NICE change

The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments.

Views & Analysis

Rises in non-submissions to NICE: do they matter?

Leela Barham asks why companies may choose to not submit their drugs to NICE and keep them off routine commissioning – a trend that appears to be on the rise.

Views & Analysis

Getting the most out of technical engagement with NICE

In 2017 the UK’s National Institute for Health and Care Excellence (NICE)

Views & Analysis

Market access in the time of COVID-19

COVID-19 has left no part of life untouched, including health technology assessment (HTA) and other payer agency activities, and it will likely have a lasting impact on market access.

Views & Analysis